C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug offers hope for Long-Term control of devastating kidney diseases
Disease control Recruiting nowThis study is for people who have already been in a related trial for the drug iptacopan. It aims to see how safe and effective the drug is over many years for two rare and serious kidney diseases, C3G and IC-MPGN. The goal is to control the disease, protect kidney function, and …
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New kidney disease drug under watch in Real-World patients
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of Fabhalta capsules in patients with C3 glomerulopathy, a rare kidney disease. It will follow about 50 patients in real-world clinical practice for up to a year. The main goal is to track infections and other side effects, wh…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 09, 2026 14:22 UTC